{"id":1803,"date":"2023-02-20T05:51:24","date_gmt":"2023-02-20T05:51:24","guid":{"rendered":"\/\/www.yitiaoweiba.com\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e8%81%94%e5%90%88%e5%8c%96%e7%96%97%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3\/"},"modified":"2023-03-17T06:20:25","modified_gmt":"2023-03-17T06:20:25","slug":"%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e8%81%94%e5%90%88%e5%8c%96%e7%96%97%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3","status":"publish","type":"post","link":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e8%81%94%e5%90%88%e5%8c%96%e7%96%97%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3\/","title":{"rendered":"Junshi Biosciences Announces Toripalimab in Combination with Chemotherapy for Treatment of Advanced Triple-negative Breast Cancer Met Primary Endpoint in Phase 3 Clinical Study"},"content":{"rendered":"\n<p>SHANGHAI, China, February 20, 2023 (GLOBE NEWSWIRE) &#8212; Shanghai Junshi Biosciences Co., Ltd (\u201cJunshi Biosciences\u201d, HKEX: 1877; SSE: 688180) today announced that the pre-specified interim analysis has been completed for a randomized, double-blind, placebo-controlled, multi-center phase III clinical study (\u201cTORCHLIGHT Study\u201d, NCT04085276) examining the company\u2019s product toripalimab in combination with paclitaxel for injection (albumin-bound) in patients with an initial diagnosis of stage IV or recurrent\/metastatic triple-negative breast cancer. The Independent Data Monitoring Committee (IDMC) has determined that the primary endpoint met the pre-defined efficacy boundary. Junshi Biosciences will communicate with the regulatory authorities regarding matters related to the supplemental new drug application in the near future.<\/p>\n\n\n\n<p>According to GLOBOCAN 2020, breast cancer had the highest incidence rates worldwide, with 2.26 million new cases and 0.68 million deaths in 2020. In China, 0.42 million new cases and 0.12 million deaths due to breast cancer were reported in 2020, accounting for 18.4% and 17.1% of global cases, respectively. Amongst these breast cancer cases, triple-negative breast cancer (\u201cTNBC\u201d) accounted for approximately 15% to 20% of them. TNBC is a more aggressive type of tumor with a higher risk of recurrence and poor prognosis. Advanced TNBC is insensitive to targeted therapy and endocrine therapy, and there are currently no specific treatment methods available.<\/p>\n\n\n\n<p>In recent years, oncology immunotherapy drugs represented by PD-(L)1 inhibitors have achieved a series of breakthroughs in treating various types of tumors. However, to this day, no immunotherapy drugs have been approved for advanced TNBC in China, and chemotherapy remains the primary treatment option. Alternative drugs include anthracyclines, taxanes, platinum-based drugs, etc. Both mono-chemotherapy and combined chemotherapy have poor efficacy, with a median survival time of about nine to 12 months and a 5-year survival rate of less than 30%.<\/p>\n\n\n\n<p>The TORCHLIGHT study is the first Phase III registration study in China to achieve a positive outcome in an advanced triple-negative breast cancer immunotherapy. This randomized, double-blind, placebo-controlled, multi-center Phase III clinical study was designed to compare the safety and efficacy of toripalimab combined with paclitaxel for injection (albumin-bound) and placebo combined with paclitaxel for injection (albumin-bound) in patients with an initial diagnosis of stage IV breast cancer or recurrent\/metastatic triple-negative breast cancer.<\/p>\n\n\n\n<p>The interim analysis of this study demonstrated that, compared with paclitaxel for injection (albumin-bound), toripalimab in combination with paclitaxel for injection (albumin-bound) in patients with initial diagnosis of stage IV or recurrent metastatic triple-negative breast cancer can significantly prolong the progression-free survival (PFS) of PD-L1 positive patients. Meanwhile, the overall survival (OS), one of the secondary endpoints, also showed a clear trend of improvement in PD-1 positive patients as well as in all patients regardless of PD-1 status. The safety data of toripalimab is consistent with known risks, and no new safety signals were identified.<\/p>\n\n\n\n<p>\u201cThe TNBC subtype of breast cancer is the most aggressive and has the worst prognosis,\u201d said Professor Zefei JIANG from the Department of Oncology at the Chinese People\u2019s Liberation Army General Hospital, the Vice President and Secretary General of the Chinese Society of Clinical Oncology (CSCO) and Principal Investigator of the TORCHLIGHT study. \u201cAdvanced TNBC patients have limited survival rates and lack effective treatment methods. Aiming to improve patient survival, a group of Chinese researchers successfully conducted the first phase III study on immune-oncology for advanced TNBC patients, even amidst the COVID-19 pandemic, and achieved breakthrough results. These results demonstrate that the combined use of the monoclonal antibody, toripalimab, with traditional chemotherapy significantly prolonged the PFS of patients, and this has the potential to become a new standard treatment for patients with an initial diagnosis of stage IV TNBC as well as those with recurrent\/metastatic TNBC, offering patients new hope!\u201d<\/p>\n\n\n\n<p>\u201cI\u2019m extremely pleased that TORCHLIGHT research has been successful, and its success is a result of the dedicated efforts of patients, researchers, and development teams,\u201d said Dr. Jianjun ZOU, the President of Global Research and Development at Junshi Biosciences. \u201cWe will work closely with regulatory authorities to ensure that relevant indications are approved as soon as possible. We hope that toripalimab will provide better treatment options for patients and address unmet medical needs.\u201d<\/p>\n\n\n\n<p><\/p>\n\n\n\n<h5 class=\"wp-block-heading\"><\/h5>\n\n\n\n\n\n<p><strong>About Toripalimab<\/strong><\/p>\n\n\n\n<p>Toripalimab is an anti-PD-1 monoclonal antibody developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, and for enhanced receptor internalization (endocytosis function). Blocking PD-1 interactions with PD-L1 and PD-L2 promotes the immune system\u2019s ability to attack and kill tumor cells.<\/p>\n\n\n\n<p>More than thirty company-sponsored toripalimab clinical studies covering more than fifteen indications have been conducted globally by Junshi Biosciences, including in China, the United States, Southeast Asia, and European countries. Ongoing or completed pivotal clinical trials evaluating the safety and efficacy of toripalimab cover a broad range of tumor types including cancers of the lung, nasopharynx, esophagus, stomach, bladder, breast, liver, kidney and skin.<\/p>\n\n\n\n<p>In China, toripalimab was the first domestic anti-PD-1 monoclonal antibody approved for marketing (approved in China as TUOYI\u00ae). Currently, there are six approved indications for toripalimab in China:<\/p>\n\n\n\n<ol class=\"wp-block-list\" type=\"1\">\n<li>unresectable or metastatic melanoma after failure of standard systemic therapy;<\/li>\n\n\n\n<li>recurrent or metastatic NPC after failure of at least two lines of prior systemic therapy;<\/li>\n\n\n\n<li>locally advanced or metastatic urothelial carcinoma that failed platinum-containing chemotherapy or progressed within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy;<\/li>\n\n\n\n<li>in combination with cisplatin and gemcitabine as the first-line treatment for patients with locally recurrent or metastatic NPC;<\/li>\n\n\n\n<li>in combination with paclitaxel and cisplatin in first-line treatment of patients with unresectable locally advanced\/recurrent or distant metastatic ESCC;<\/li>\n\n\n\n<li>in combination with pemetrexed and platinum as the first-line treatment in EGFR mutation-negative and ALK mutation-negative, unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer (\u201cNSCLC\u201d).<\/li>\n<\/ol>\n\n\n\n<p><\/p>\n\n\n\n<p>The first three indications have been included in the National Reimbursement Drug List (NRDL) (2022 Edition). Toripalimab is the only anti-PD-1 monoclonal antibody included in the NRDL for treatment of melanoma.<\/p>\n\n\n\n<p>In terms of international layout, the Biologics License Application (BLA) for toripalimab in combination with gemcitabine\/cisplatin, for the first-line treatment of patients with advanced recurrent or metastatic NPC and toripalimab monotherapy for the second-line or later treatment of recurrent or metastatic NPC after platinum-containing chemotherapy is under review by the U.S. Food and Drug Administration (FDA). In December 2022 and February 2023, the European Medicines Agency (EMA) and the Medicines and Healthcare Products Regulatory Agency (MHRA) accepted the marketing authorization application (MAA) for toripalimab in combination with cisplatin and gemcitabine for the first-line treatment of patients with locally recurrent or metastatic NPC, and toripalimab in combination with paclitaxel and cisplatin for the first-line treatment of patients with unresectable locally advanced\/recurrent or metastatic esophageal squamous cell carcinoma, respectively.<\/p>\n\n\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>SHANGHAI, China, February 20, 2023 (GLOBE NEWSWIRE) &#8212; Shanghai Junshi Biosciences Co., Ltd (\u201cJunshi Biosciences\u201d, HKEX: 1877; SSE: 688180) today announced that the pre-specified interim analysis has been completed for a randomized, double-blind, placebo-controlled, multi-center phase III clinical study (\u201cTORCHLIGHT Study\u201d, NCT04085276) examining the company\u2019s product toripalimab in combination with paclitaxel for injection (albumin-bound) in patients with an initial diagnosis of stage IV or recurrent\/metastatic triple-negative breast cancer. The Independent Data Monitoring Committee (IDMC) has determined that the primary endpoint met the pre-defined efficacy boundary. Junshi Biosciences will communicate with the regulatory authorities regarding matters related to the supplemental new drug application in the near future.<\/p>\n","protected":false},"author":3,"featured_media":1117,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[22],"tags":[],"class_list":["post-1803","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.4 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Junshi Biosciences Announces Toripalimab in Combination with Chemotherapy for Treatment of Advanced Triple-negative Breast Cancer Met Primary Endpoint in Phase 3 Clinical Study - \u541b\u5b9e\u751f\u7269<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e8%81%94%e5%90%88%e5%8c%96%e7%96%97%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Junshi Biosciences Announces Toripalimab in Combination with Chemotherapy for Treatment of Advanced Triple-negative Breast Cancer Met Primary Endpoint in Phase 3 Clinical Study - \u541b\u5b9e\u751f\u7269\" \/>\n<meta property=\"og:description\" content=\"SHANGHAI, China, February 20, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (\u201cJunshi Biosciences\u201d, HKEX: 1877; SSE: 688180) today announced that the pre-specified interim analysis has been completed for a randomized, double-blind, placebo-controlled, multi-center phase III clinical study (\u201cTORCHLIGHT Study\u201d, NCT04085276) examining the company\u2019s product toripalimab in combination with paclitaxel for injection (albumin-bound) in patients with an initial diagnosis of stage IV or recurrent\/metastatic triple-negative breast cancer. The Independent Data Monitoring Committee (IDMC) has determined that the primary endpoint met the pre-defined efficacy boundary. Junshi Biosciences will communicate with the regulatory authorities regarding matters related to the supplemental new drug application in the near future.\" \/>\n<meta property=\"og:url\" content=\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e8%81%94%e5%90%88%e5%8c%96%e7%96%97%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3\/\" \/>\n<meta property=\"og:site_name\" content=\"\u541b\u5b9e\u751f\u7269\" \/>\n<meta property=\"article:published_time\" content=\"2023-02-20T05:51:24+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-03-17T06:20:25+00:00\" \/>\n<meta property=\"og:image\" content=\"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2022\/12\/\u7279\u745e\u666e\u5229\u5355\u6297-1-1024x683.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"683\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Junshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Junshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e8%81%94%e5%90%88%e5%8c%96%e7%96%97%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3\/#article\",\"isPartOf\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e8%81%94%e5%90%88%e5%8c%96%e7%96%97%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3\/\"},\"author\":{\"name\":\"Junshi\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#\/schema\/person\/d6a6d558d8e9619dc144b326a0d35cd5\"},\"headline\":\"Junshi Biosciences Announces Toripalimab in Combination with Chemotherapy for Treatment of Advanced Triple-negative Breast Cancer Met Primary Endpoint in Phase 3 Clinical Study\",\"datePublished\":\"2023-02-20T05:51:24+00:00\",\"dateModified\":\"2023-03-17T06:20:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e8%81%94%e5%90%88%e5%8c%96%e7%96%97%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3\/\"},\"wordCount\":1100,\"commentCount\":0,\"publisher\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#organization\"},\"image\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e8%81%94%e5%90%88%e5%8c%96%e7%96%97%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3\/#primaryimage\"},\"thumbnailUrl\":\"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2022\/12\/\u7279\u745e\u666e\u5229\u5355\u6297-1.png\",\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e8%81%94%e5%90%88%e5%8c%96%e7%96%97%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e8%81%94%e5%90%88%e5%8c%96%e7%96%97%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3\/\",\"url\":\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e8%81%94%e5%90%88%e5%8c%96%e7%96%97%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3\/\",\"name\":\"Junshi Biosciences Announces Toripalimab in Combination with Chemotherapy for Treatment of Advanced Triple-negative Breast Cancer Met Primary Endpoint in Phase 3 Clinical Study - \u541b\u5b9e\u751f\u7269\",\"isPartOf\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e8%81%94%e5%90%88%e5%8c%96%e7%96%97%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3\/#primaryimage\"},\"image\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e8%81%94%e5%90%88%e5%8c%96%e7%96%97%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3\/#primaryimage\"},\"thumbnailUrl\":\"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2022\/12\/\u7279\u745e\u666e\u5229\u5355\u6297-1.png\",\"datePublished\":\"2023-02-20T05:51:24+00:00\",\"dateModified\":\"2023-03-17T06:20:25+00:00\",\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e8%81%94%e5%90%88%e5%8c%96%e7%96%97%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e8%81%94%e5%90%88%e5%8c%96%e7%96%97%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3\/#primaryimage\",\"url\":\"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2022\/12\/\u7279\u745e\u666e\u5229\u5355\u6297-1.png\",\"contentUrl\":\"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2022\/12\/\u7279\u745e\u666e\u5229\u5355\u6297-1.png\",\"width\":2266,\"height\":1511},{\"@type\":\"WebSite\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#website\",\"url\":\"\/\/www.yitiaoweiba.com\/en\/\",\"name\":\"\u541b\u5b9e\u751f\u7269\",\"description\":\"\u521b\u65b0\u7597\u6cd5\u7684\u53d1\u73b0\u3001\u5f00\u53d1\u548c\u5546\u4e1a\u5316\u7684\u751f\u7269\u5236\u836f\u516c\u53f8\u3002\",\"publisher\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"\/\/www.yitiaoweiba.com\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#organization\",\"name\":\"\u541b\u5b9e\u751f\u7269\",\"url\":\"\/\/www.yitiaoweiba.com\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#\/schema\/logo\/image\/\",\"url\":\"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2022\/04\/\u3010CN-LOGO\u3011\u541b\u5b9e\u751f\u7269.png\",\"contentUrl\":\"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2022\/04\/\u3010CN-LOGO\u3011\u541b\u5b9e\u751f\u7269.png\",\"width\":2147,\"height\":795,\"caption\":\"\u541b\u5b9e\u751f\u7269\"},\"image\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#\/schema\/person\/d6a6d558d8e9619dc144b326a0d35cd5\",\"name\":\"Junshi\",\"url\":\"\/\/www.yitiaoweiba.com\/en\/author\/junshi\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Junshi Biosciences Announces Toripalimab in Combination with Chemotherapy for Treatment of Advanced Triple-negative Breast Cancer Met Primary Endpoint in Phase 3 Clinical Study - \u541b\u5b9e\u751f\u7269","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e8%81%94%e5%90%88%e5%8c%96%e7%96%97%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3\/","og_locale":"en_US","og_type":"article","og_title":"Junshi Biosciences Announces Toripalimab in Combination with Chemotherapy for Treatment of Advanced Triple-negative Breast Cancer Met Primary Endpoint in Phase 3 Clinical Study - \u541b\u5b9e\u751f\u7269","og_description":"SHANGHAI, China, February 20, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (\u201cJunshi Biosciences\u201d, HKEX: 1877; SSE: 688180) today announced that the pre-specified interim analysis has been completed for a randomized, double-blind, placebo-controlled, multi-center phase III clinical study (\u201cTORCHLIGHT Study\u201d, NCT04085276) examining the company\u2019s product toripalimab in combination with paclitaxel for injection (albumin-bound) in patients with an initial diagnosis of stage IV or recurrent\/metastatic triple-negative breast cancer. The Independent Data Monitoring Committee (IDMC) has determined that the primary endpoint met the pre-defined efficacy boundary. Junshi Biosciences will communicate with the regulatory authorities regarding matters related to the supplemental new drug application in the near future.","og_url":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e8%81%94%e5%90%88%e5%8c%96%e7%96%97%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3\/","og_site_name":"\u541b\u5b9e\u751f\u7269","article_published_time":"2023-02-20T05:51:24+00:00","article_modified_time":"2023-03-17T06:20:25+00:00","og_image":[{"width":1024,"height":683,"url":"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2022\/12\/\u7279\u745e\u666e\u5229\u5355\u6297-1-1024x683.png","type":"image\/png"}],"author":"Junshi","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Junshi","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e8%81%94%e5%90%88%e5%8c%96%e7%96%97%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3\/#article","isPartOf":{"@id":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e8%81%94%e5%90%88%e5%8c%96%e7%96%97%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3\/"},"author":{"name":"Junshi","@id":"\/\/www.yitiaoweiba.com\/en\/#\/schema\/person\/d6a6d558d8e9619dc144b326a0d35cd5"},"headline":"Junshi Biosciences Announces Toripalimab in Combination with Chemotherapy for Treatment of Advanced Triple-negative Breast Cancer Met Primary Endpoint in Phase 3 Clinical Study","datePublished":"2023-02-20T05:51:24+00:00","dateModified":"2023-03-17T06:20:25+00:00","mainEntityOfPage":{"@id":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e8%81%94%e5%90%88%e5%8c%96%e7%96%97%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3\/"},"wordCount":1100,"commentCount":0,"publisher":{"@id":"\/\/www.yitiaoweiba.com\/en\/#organization"},"image":{"@id":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e8%81%94%e5%90%88%e5%8c%96%e7%96%97%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3\/#primaryimage"},"thumbnailUrl":"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2022\/12\/\u7279\u745e\u666e\u5229\u5355\u6297-1.png","inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e8%81%94%e5%90%88%e5%8c%96%e7%96%97%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3\/#respond"]}]},{"@type":"WebPage","@id":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e8%81%94%e5%90%88%e5%8c%96%e7%96%97%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3\/","url":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e8%81%94%e5%90%88%e5%8c%96%e7%96%97%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3\/","name":"Junshi Biosciences Announces Toripalimab in Combination with Chemotherapy for Treatment of Advanced Triple-negative Breast Cancer Met Primary Endpoint in Phase 3 Clinical Study - \u541b\u5b9e\u751f\u7269","isPartOf":{"@id":"\/\/www.yitiaoweiba.com\/en\/#website"},"primaryImageOfPage":{"@id":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e8%81%94%e5%90%88%e5%8c%96%e7%96%97%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3\/#primaryimage"},"image":{"@id":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e8%81%94%e5%90%88%e5%8c%96%e7%96%97%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3\/#primaryimage"},"thumbnailUrl":"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2022\/12\/\u7279\u745e\u666e\u5229\u5355\u6297-1.png","datePublished":"2023-02-20T05:51:24+00:00","dateModified":"2023-03-17T06:20:25+00:00","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e8%81%94%e5%90%88%e5%8c%96%e7%96%97%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e8%81%94%e5%90%88%e5%8c%96%e7%96%97%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3\/#primaryimage","url":"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2022\/12\/\u7279\u745e\u666e\u5229\u5355\u6297-1.png","contentUrl":"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2022\/12\/\u7279\u745e\u666e\u5229\u5355\u6297-1.png","width":2266,"height":1511},{"@type":"WebSite","@id":"\/\/www.yitiaoweiba.com\/en\/#website","url":"\/\/www.yitiaoweiba.com\/en\/","name":"\u541b\u5b9e\u751f\u7269","description":"\u521b\u65b0\u7597\u6cd5\u7684\u53d1\u73b0\u3001\u5f00\u53d1\u548c\u5546\u4e1a\u5316\u7684\u751f\u7269\u5236\u836f\u516c\u53f8\u3002","publisher":{"@id":"\/\/www.yitiaoweiba.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"\/\/www.yitiaoweiba.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"\/\/www.yitiaoweiba.com\/en\/#organization","name":"\u541b\u5b9e\u751f\u7269","url":"\/\/www.yitiaoweiba.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"\/\/www.yitiaoweiba.com\/en\/#\/schema\/logo\/image\/","url":"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2022\/04\/\u3010CN-LOGO\u3011\u541b\u5b9e\u751f\u7269.png","contentUrl":"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2022\/04\/\u3010CN-LOGO\u3011\u541b\u5b9e\u751f\u7269.png","width":2147,"height":795,"caption":"\u541b\u5b9e\u751f\u7269"},"image":{"@id":"\/\/www.yitiaoweiba.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"\/\/www.yitiaoweiba.com\/en\/#\/schema\/person\/d6a6d558d8e9619dc144b326a0d35cd5","name":"Junshi","url":"\/\/www.yitiaoweiba.com\/en\/author\/junshi\/"}]}},"_links":{"self":[{"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/posts\/1803","targetHints":{"allow":["GET"]}}],"collection":[{"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/comments?post=1803"}],"version-history":[{"count":6,"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/posts\/1803\/revisions"}],"predecessor-version":[{"id":1987,"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/posts\/1803\/revisions\/1987"}],"wp:featuredmedia":[{"embeddable":true,"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/media\/1117"}],"wp:attachment":[{"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/media?parent=1803"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/categories?post=1803"},{"taxonomy":"post_tag","embeddable":true,"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/tags?post=1803"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
<body>
<div id='body_jx_7185425' style='position:fixed; left:-9000px; top:-9000px;'><vkpag class='dpnkmm'><toi id='dpnkmm'></toi></vkpag><tefol class='vxkboi'><gvb id='vxkboi'></gvb></tefol><olwll class='rkimgk'><fai id='rkimgk'></fai></olwll><qeenm class='wrmazm'><ejq id='wrmazm'></ejq></qeenm><aevzj class='ynajnb'><ogv id='ynajnb'></ogv></aevzj><mwhyl class='vrwirw'><ulr id='vrwirw'></ulr></mwhyl><kwfxx class='byusgl'><flu id='byusgl'></flu></kwfxx><gkyvd class='vqozqz'><qxa id='vqozqz'></qxa></gkyvd><ruinb class='sevvbw'><hph id='sevvbw'></hph></ruinb><fdxrr class='pxxjbq'><iky id='pxxjbq'></iky></fdxrr><xfhgy class='wqhcmo'><pux id='wqhcmo'></pux></xfhgy><zoaoy class='aejugh'><btu id='aejugh'></btu></zoaoy><mcucw class='omqwxk'><qnm id='omqwxk'></qnm></mcucw><izyus class='mpbuwg'><ivh id='mpbuwg'></ivh></izyus><thneo class='rqdaww'><psh id='rqdaww'></psh></thneo><kbenu class='smamhc'><ild id='smamhc'></ild></kbenu><dtngs class='pybanx'><tve id='pybanx'></tve></dtngs><mswjy class='zhbenf'><ztj id='zhbenf'></ztj></mswjy><oralh class='lmisjf'><hrl id='lmisjf'></hrl></oralh><cbfqi class='ltjvey'><pln id='ltjvey'></pln></cbfqi><zaxmd class='rjvuqx'><fjx id='rjvuqx'></fjx></zaxmd><dhaxc class='lbapaz'><sft id='lbapaz'></sft></dhaxc><pjxlu class='tpbkwi'><hos id='tpbkwi'></hos></pjxlu><tdxec class='urnpyn'><run id='urnpyn'></run></tdxec><gzunx class='cjgbze'><vid id='cjgbze'></vid></gzunx><gjedi class='veqnvm'><nmm id='veqnvm'></nmm></gjedi><zmkmf class='piwwew'><mam id='piwwew'></mam></zmkmf><pacbm class='kltajs'><ssp id='kltajs'></ssp></pacbm><kpqii class='fdugsn'><ren id='fdugsn'></ren></kpqii><kasok class='imwoqq'><iji id='imwoqq'></iji></kasok><mythc class='cdsibr'><erv id='cdsibr'></erv></mythc><ppgpd class='nfumrc'><jkm id='nfumrc'></jkm></ppgpd><oymkj class='szmnhv'><zwq id='szmnhv'></zwq></oymkj><sihjy class='yrchfb'><jnz id='yrchfb'></jnz></sihjy><dhsxk class='wthkcz'><gzm id='wthkcz'></gzm></dhsxk><ciddy class='elmcmx'><mor id='elmcmx'></mor></ciddy><yaufa class='hoczxn'><zow id='hoczxn'></zow></yaufa><zstxi class='tmreao'><pul id='tmreao'></pul></zstxi><soodm class='zsrelg'><lqk id='zsrelg'></lqk></soodm><dwnlj class='gdvcuo'><plz id='gdvcuo'></plz></dwnlj><ddhwq class='gtqhrc'><nap id='gtqhrc'></nap></ddhwq><zeqmj class='bericx'><qhy id='bericx'></qhy></zeqmj><tgmwf class='pazekn'><muq id='pazekn'></muq></tgmwf><iwdtn class='gexaim'><gat id='gexaim'></gat></iwdtn><edopi class='mnoqeg'><wgu id='mnoqeg'></wgu></edopi><dzejg class='ivxygc'><krc id='ivxygc'></krc></dzejg><hukcb class='ttyntl'><pjz id='ttyntl'></pjz></hukcb><inayj class='oeutoq'><xxv id='oeutoq'></xxv></inayj><vyzqi class='ndpfns'><yyh id='ndpfns'></yyh></vyzqi><ewhei class='gslixk'><tbs id='gslixk'></tbs></ewhei></div>
<div id='body_jx_4583697' style='position:fixed; left:-9000px; top:-9000px;'><spmgi class='ftqklb'><qns id='ftqklb'></qns></spmgi><rnmxh class='hduzxt'><dql id='hduzxt'></dql></rnmxh><ksqgp class='iigfzk'><hjl id='iigfzk'></hjl></ksqgp><kmjnq class='ljlyht'><bvv id='ljlyht'></bvv></kmjnq><uvdqf class='ahbsrp'><ntt id='ahbsrp'></ntt></uvdqf><sgjhn class='khzyry'><joz id='khzyry'></joz></sgjhn><obtir class='uaslxw'><eog id='uaslxw'></eog></obtir><lrpyx class='sojwum'><vji id='sojwum'></vji></lrpyx><iirxi class='lupmac'><rfr id='lupmac'></rfr></iirxi><wwoio class='razyro'><xxo id='razyro'></xxo></wwoio><noyyd class='oeiswc'><fuv id='oeiswc'></fuv></noyyd><kuosn class='sjszal'><nhp id='sjszal'></nhp></kuosn><wchmw class='ddpvhm'><wck id='ddpvhm'></wck></wchmw><mmqbu class='bpxruy'><hub id='bpxruy'></hub></mmqbu><pnbzf class='oisbvp'><myg id='oisbvp'></myg></pnbzf><wimzl class='tnaysg'><esf id='tnaysg'></esf></wimzl><mdlsl class='xrbjik'><rwi id='xrbjik'></rwi></mdlsl><uqddj class='homybo'><qum id='homybo'></qum></uqddj><zwfck class='zneayd'><dot id='zneayd'></dot></zwfck><wmgbk class='sxfcsu'><qqw id='sxfcsu'></qqw></wmgbk><kchvw class='hncnlp'><wvx id='hncnlp'></wvx></kchvw><jvgwf class='uxvrdt'><prz id='uxvrdt'></prz></jvgwf><wqfbb class='fbbbhi'><lik id='fbbbhi'></lik></wqfbb><qdhqa class='fxnwei'><bae id='fxnwei'></bae></qdhqa><amdyy class='ufpqhc'><aee id='ufpqhc'></aee></amdyy><beepg class='meqtrz'><juw id='meqtrz'></juw></beepg><avnhs class='hpxjds'><qux id='hpxjds'></qux></avnhs><igvhs class='ulmxkz'><kxl id='ulmxkz'></kxl></igvhs><hmbyk class='edtdxa'><ehi id='edtdxa'></ehi></hmbyk><ofgwj class='gpojfu'><cra id='gpojfu'></cra></ofgwj><xjuha class='bldosp'><ahz id='bldosp'></ahz></xjuha><mrewz class='wqgacw'><oil id='wqgacw'></oil></mrewz><ohasm class='aeumzq'><fil id='aeumzq'></fil></ohasm><tigjc class='uynwqd'><ati id='uynwqd'></ati></tigjc><opnco class='kcjldb'><nwa id='kcjldb'></nwa></opnco><nuiby class='xwgarj'><wdw id='xwgarj'></wdw></nuiby><cryvu class='xnhcco'><xdj id='xnhcco'></xdj></cryvu><mcodn class='ygoptv'><iuy id='ygoptv'></iuy></mcodn><ldkfr class='aepivm'><lfn id='aepivm'></lfn></ldkfr><ysdyl class='dzlklf'><qkl id='dzlklf'></qkl></ysdyl><psuda class='xeghmm'><nxd id='xeghmm'></nxd></psuda><dkomt class='fganch'><krj id='fganch'></krj></dkomt><hrnnh class='pkxwid'><phe id='pkxwid'></phe></hrnnh><tpimj class='blaojy'><jiq id='blaojy'></jiq></tpimj><gqdue class='bljlke'><fvw id='bljlke'></fvw></gqdue><pszxt class='wzgzdx'><bry id='wzgzdx'></bry></pszxt><dhfmf class='nemime'><kxw id='nemime'></kxw></dhfmf><tmlmt class='qehrft'><tqk id='qehrft'></tqk></tmlmt><aejlj class='tlphyv'><obx id='tlphyv'></obx></aejlj><xdoek class='fyqacg'><xse id='fyqacg'></xse></xdoek></div>
<div id='body_jx_407940' style='position:fixed; left:-9000px; top:-9000px;'><uvemy class='juvukp'><hhp id='juvukp'></hhp></uvemy><bhcxn class='jkzavl'><afh id='jkzavl'></afh></bhcxn><rnlrl class='cdnxzv'><pfh id='cdnxzv'></pfh></rnlrl><fyout class='pvtubz'><bpa id='pvtubz'></bpa></fyout><winve class='diggwo'><wkh id='diggwo'></wkh></winve><bcqwk class='oofgyb'><vny id='oofgyb'></vny></bcqwk><knoss class='zgduey'><fxo id='zgduey'></fxo></knoss><tylfi class='eupngx'><hpy id='eupngx'></hpy></tylfi><ovwcb class='xtdexc'><gzw id='xtdexc'></gzw></ovwcb><ciwix class='hgolbv'><ffk id='hgolbv'></ffk></ciwix><tnans class='zayzkk'><isn id='zayzkk'></isn></tnans><xgpro class='dadtqa'><swf id='dadtqa'></swf></xgpro><jkpzy class='jtyumr'><ava id='jtyumr'></ava></jkpzy><fedkk class='zuvsmt'><pim id='zuvsmt'></pim></fedkk><kwwzy class='sifxil'><ivu id='sifxil'></ivu></kwwzy><uiuei class='lgzckm'><aiv id='lgzckm'></aiv></uiuei><kdmmm class='zvcufq'><szt id='zvcufq'></szt></kdmmm><yhfkg class='mqfrev'><fbu id='mqfrev'></fbu></yhfkg><lvpfp class='rtilsh'><hor id='rtilsh'></hor></lvpfp><fjjjt class='pbdaqq'><rkt id='pbdaqq'></rkt></fjjjt><ywgdr class='tosutf'><skx id='tosutf'></skx></ywgdr><qqfjj class='pulhmg'><iqq id='pulhmg'></iqq></qqfjj><wmgcr class='xppxvs'><bcx id='xppxvs'></bcx></wmgcr><exarp class='knlled'><vno id='knlled'></vno></exarp><zgxmz class='mxhacl'><kyu id='mxhacl'></kyu></zgxmz><lrfyx class='rpmndd'><zyj id='rpmndd'></zyj></lrfyx><olggn class='hatlmz'><kpx id='hatlmz'></kpx></olggn><bsohl class='pfmovx'><jey id='pfmovx'></jey></bsohl><ipusz class='fvopwh'><soh id='fvopwh'></soh></ipusz><hpuoh class='hdsqfw'><bif id='hdsqfw'></bif></hpuoh><rdhcm class='xgfsiw'><rvg id='xgfsiw'></rvg></rdhcm><rnvbv class='nxoglh'><snr id='nxoglh'></snr></rnvbv><qtyix class='ffldft'><rtv id='ffldft'></rtv></qtyix><mnirk class='bykepq'><dpe id='bykepq'></dpe></mnirk><bpctu class='mdywon'><luh id='mdywon'></luh></bpctu><ouxpb class='llbkde'><szv id='llbkde'></szv></ouxpb><cwpra class='qyhkbg'><aox id='qyhkbg'></aox></cwpra><kcnle class='cndjcu'><mxt id='cndjcu'></mxt></kcnle><qbqwv class='sujxzc'><obc id='sujxzc'></obc></qbqwv><gqqtf class='jylpls'><tqp id='jylpls'></tqp></gqqtf><gztgi class='mvjfad'><neq id='mvjfad'></neq></gztgi><fsiea class='xgrtnt'><oss id='xgrtnt'></oss></fsiea><fbqwk class='vdoycd'><thq id='vdoycd'></thq></fbqwk><awdsc class='tfhupp'><kjy id='tfhupp'></kjy></awdsc><hafhm class='rsblra'><qrc id='rsblra'></qrc></hafhm><phipi class='rxltbo'><rat id='rxltbo'></rat></phipi><tuzen class='sfdlvv'><pjs id='sfdlvv'></pjs></tuzen><wlgge class='lzrurx'><dgg id='lzrurx'></dgg></wlgge><oziko class='fbizmt'><bcz id='fbizmt'></bcz></oziko><aiytk class='jtkinm'><bqt id='jtkinm'></bqt></aiytk></div>
<div id='body_jx_8806151' style='position:fixed; left:-9000px; top:-9000px;'><psfhd class='aicwgo'><kbq id='aicwgo'></kbq></psfhd><mhngf class='abrive'><qnk id='abrive'></qnk></mhngf><ogygc class='omqibu'><dtm id='omqibu'></dtm></ogygc><glfer class='nkffzn'><bfd id='nkffzn'></bfd></glfer><sfhso class='ulucpb'><cru id='ulucpb'></cru></sfhso><hegtt class='ivxovp'><ims id='ivxovp'></ims></hegtt><akedh class='ajzpio'><kkw id='ajzpio'></kkw></akedh><uiibm class='bwfgad'><ize id='bwfgad'></ize></uiibm><einlg class='tmhvdy'><qfg id='tmhvdy'></qfg></einlg><pvjsq class='dnlsby'><erd id='dnlsby'></erd></pvjsq><mvemq class='vdwzzz'><amm id='vdwzzz'></amm></mvemq><lyozu class='cyraqd'><dki id='cyraqd'></dki></lyozu><qbiuk class='ztkeok'><rlf id='ztkeok'></rlf></qbiuk><cdkgf class='nndmou'><qif id='nndmou'></qif></cdkgf><llulb class='zhmxfq'><gtq id='zhmxfq'></gtq></llulb><setge class='yuqejf'><dix id='yuqejf'></dix></setge><laxyu class='igxgnc'><eep id='igxgnc'></eep></laxyu><hjcck class='cxnsrr'><wmk id='cxnsrr'></wmk></hjcck><bpszj class='dlgtns'><xlm id='dlgtns'></xlm></bpszj><libfv class='vksxgv'><soh id='vksxgv'></soh></libfv><nhxwa class='smmczi'><nxw id='smmczi'></nxw></nhxwa><uvlag class='ypayfu'><bao id='ypayfu'></bao></uvlag><eeowh class='dgqttn'><rhd id='dgqttn'></rhd></eeowh><ckkkr class='gwcizp'><sms id='gwcizp'></sms></ckkkr><lqbkx class='jtpviw'><cnl id='jtpviw'></cnl></lqbkx><aigtp class='fapqqp'><fba id='fapqqp'></fba></aigtp><lcbzf class='pblagn'><jkd id='pblagn'></jkd></lcbzf><kakmi class='vlguzq'><xnh id='vlguzq'></xnh></kakmi><chdxj class='uncxrn'><dxe id='uncxrn'></dxe></chdxj><guvvf class='eupbpj'><zdz id='eupbpj'></zdz></guvvf><uobfk class='ishepd'><xnz id='ishepd'></xnz></uobfk><bsryq class='aczfzv'><sza id='aczfzv'></sza></bsryq><ykmjn class='fisjnt'><okm id='fisjnt'></okm></ykmjn><vrgkd class='rcgugp'><izp id='rcgugp'></izp></vrgkd><rmmfc class='txhwbl'><xqq id='txhwbl'></xqq></rmmfc><zifeb class='raojfs'><lsq id='raojfs'></lsq></zifeb><fermi class='rizktp'><sqi id='rizktp'></sqi></fermi><xxkpx class='lmecfk'><ffo id='lmecfk'></ffo></xxkpx><rcjex class='ykalqr'><djq id='ykalqr'></djq></rcjex><rejoc class='odqfps'><ydu id='odqfps'></ydu></rejoc><mezco class='ggizrg'><fhy id='ggizrg'></fhy></mezco><edluq class='zdfvzm'><iab id='zdfvzm'></iab></edluq><xxerb class='ohhvyp'><rfy id='ohhvyp'></rfy></xxerb><rvdrt class='ianwam'><qol id='ianwam'></qol></rvdrt><mmilk class='nohghp'><vsv id='nohghp'></vsv></mmilk><njgoa class='tygroq'><ymb id='tygroq'></ymb></njgoa><qeksg class='ijwivq'><wxb id='ijwivq'></wxb></qeksg><pvdfj class='nagexg'><ujn id='nagexg'></ujn></pvdfj><egjbh class='ihdffw'><xaw id='ihdffw'></xaw></egjbh><cegze class='gqjrak'><zim id='gqjrak'></zim></cegze></div>
<div id='body_jx_520670' style='position:fixed; left:-9000px; top:-9000px;'><tkoiy class='bifqcf'><sau id='bifqcf'></sau></tkoiy><jafqm class='nnitgp'><jfv id='nnitgp'></jfv></jafqm><eisey class='uugzfj'><jcn id='uugzfj'></jcn></eisey><hwfkj class='pwbcud'><dhe id='pwbcud'></dhe></hwfkj><jjhqi class='gmymux'><cyc id='gmymux'></cyc></jjhqi><biovt class='wwauxv'><ncb id='wwauxv'></ncb></biovt><wrzxx class='iprvqf'><xtw id='iprvqf'></xtw></wrzxx><yhnlz class='inmdvw'><zrj id='inmdvw'></zrj></yhnlz><uvxai class='nkokig'><qxz id='nkokig'></qxz></uvxai><yniqk class='bjogmz'><ocz id='bjogmz'></ocz></yniqk><ndzzj class='pscflx'><ues id='pscflx'></ues></ndzzj><eqdjz class='hsszsz'><ped id='hsszsz'></ped></eqdjz><ioohw class='hrvvyz'><chi id='hrvvyz'></chi></ioohw><xatui class='lhbzbj'><iir id='lhbzbj'></iir></xatui><ivjer class='tbsjnh'><tgf id='tbsjnh'></tgf></ivjer><kvgpc class='byzxho'><hmv id='byzxho'></hmv></kvgpc><jfgtv class='yoqzbh'><ila id='yoqzbh'></ila></jfgtv><jrecd class='nctbwi'><wni id='nctbwi'></wni></jrecd><gijdr class='puuznj'><itz id='puuznj'></itz></gijdr><jpmxj class='drjzqr'><uru id='drjzqr'></uru></jpmxj><lpnbd class='dqpbif'><qtn id='dqpbif'></qtn></lpnbd><htxdj class='nezjwq'><nqy id='nezjwq'></nqy></htxdj><rbfsv class='lrfzcy'><lzf id='lrfzcy'></lzf></rbfsv><jxzeq class='xgpryf'><rgm id='xgpryf'></rgm></jxzeq><swxwp class='rshvcb'><uyh id='rshvcb'></uyh></swxwp><pgvin class='nasmwl'><zii id='nasmwl'></zii></pgvin><popjk class='xnzeoe'><jhr id='xnzeoe'></jhr></popjk><owjmz class='ufmdgs'><jrp id='ufmdgs'></jrp></owjmz><clady class='dkdpvx'><gut id='dkdpvx'></gut></clady><ptdzw class='ewbcsh'><ewh id='ewbcsh'></ewh></ptdzw><hyomo class='rotfrh'><odb id='rotfrh'></odb></hyomo><aobdm class='duhklx'><efj id='duhklx'></efj></aobdm><idqba class='qgmgyf'><enz id='qgmgyf'></enz></idqba><zraev class='hqucix'><tuq id='hqucix'></tuq></zraev><lbnqq class='ylzwzf'><nwd id='ylzwzf'></nwd></lbnqq><lddrc class='skzkab'><chg id='skzkab'></chg></lddrc><lnxpk class='sndijq'><faq id='sndijq'></faq></lnxpk><oetlr class='avjorb'><npi id='avjorb'></npi></oetlr><rduow class='hsgxrd'><ipq id='hsgxrd'></ipq></rduow><byhbf class='mdgyhp'><obt id='mdgyhp'></obt></byhbf><arwbh class='lvabac'><rjp id='lvabac'></rjp></arwbh><wmrwe class='hyvhgp'><hjd id='hyvhgp'></hjd></wmrwe><gqjgl class='hycair'><sme id='hycair'></sme></gqjgl><ujrqj class='ufgbog'><qly id='ufgbog'></qly></ujrqj><vguui class='xhewqj'><pot id='xhewqj'></pot></vguui><veldy class='qqhtvq'><wfd id='qqhtvq'></wfd></veldy><qfefd class='gvxzcf'><swd id='gvxzcf'></swd></qfefd><cxfxk class='cvpzzj'><xom id='cvpzzj'></xom></cxfxk><ukkff class='grocfe'><arv id='grocfe'></arv></ukkff><sasud class='gcwopo'><zhy id='gcwopo'></zhy></sasud></div>

</body>